# Hypochondroplasia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hypochondroplasia

> 5 upcoming FDA catalysts in hypochondroplasia: VOXZOGO (vosoritide, BMRN) on May 30, 2027 (PDUFA date); VOXZOGO (vosoritide, BMRN) on Jun to Sep 2028 (topline data readout); VOXZOGO (vosoritide, BMRN) on June 2028 (primary completion); YUVIWEL® (navepegritide, ASND) on October 2028 (primary completion); and 1 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for hypochondroplasia?

5 upcoming FDA catalysts in hypochondroplasia: VOXZOGO (vosoritide, BMRN) on May 30, 2027 (PDUFA date); VOXZOGO (vosoritide, BMRN) on Jun to Sep 2028 (topline data readout); VOXZOGO (vosoritide, BMRN) on June 2028 (primary completion); YUVIWEL® (navepegritide, ASND) on October 2028 (primary completion); and 1 more. Press release filed with the SEC (EX-99): "PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH)" [Calendar and source filings](https://sec-api.dev/indications/hypochondroplasia)

Source: Press release filed with the SEC (EX-99), accession 0001048477-26-000021, https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/indications/hypochondroplasia#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 23, 2026 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | completed | "NCT06455059 (Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455059)) |
| Jul 2026 | [VOXZOGO (vosoritide) NDA/BLA submission](https://sec-api.dev/pdufa/vosoritide) | BMRN | hypochondroplasia | completed | "•In July 2026, we submitted our supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia following our announcement in May 2026 that the Phase 3 CANOPY-HCH-3 study met its primary endpoint." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm)) |
| May 30, 2027 | [VOXZOGO (vosoritide) PDUFA date](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | scheduled | "PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm)) |
| Jun to Sep 2028 | [VOXZOGO (vosoritide) topline data readout](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | scheduled | "NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07126262)) |
| June 2028 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | scheduled | "NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07126262)) |
| October 2028 | [YUVIWEL® (navepegritide) primary completion](https://sec-api.dev/pdufa/navepegritide) | ASND | Hypochondroplasia | scheduled | "NCT07917143 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07917143)) |
| Oct 2028 to Jan 2029 | [YUVIWEL® (navepegritide) topline data readout](https://sec-api.dev/pdufa/navepegritide) | ASND | Hypochondroplasia | scheduled | "NCT07917143 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07917143)) |

## Drugs

- [VOXZOGO (vosoritide)](https://sec-api.dev/pdufa/vosoritide) (BMRN)
- [YUVIWEL® (navepegritide)](https://sec-api.dev/pdufa/navepegritide) (ASND)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hypochondroplasia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hypochondroplasia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hypochondroplasia

```bibtex
@misc{secapidev_indications_hypochondroplasia_20261116,
  title        = {Hypochondroplasia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hypochondroplasia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hypochondroplasia_20261116","title":"Hypochondroplasia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hypochondroplasia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
